Device Trial Radar · NCT05935007
Aveir DR Real-World Evidence Post-Approval Study
Last checked: Nov 19, 2026Latest source record: May 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,805
Planned (sponsor's estimate)
Start
Oct 31, 2023
Primary completion
Dec 31, 2030
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- Abbott Medical DevicesPublic (ABT)
- Sponsor type
- Industry
- First posted
- Jul 7, 2023
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this post-approval study is to evaluate the long-term safety of the dual-chamber Aveir DR leadless pacemaker using real-world evidence methods.
Conditions
- Cardiac Pacemaker
- Arrythmia
- Bradycardia
Interventions
Aveir DR Leadless Pacemaker SystemDevice
This study will utilize real-world data from patients implanted with the Aveir DR Leadless Pacemaker System. No device intervention will be conducted in this study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects Free from Acute Aveir DR System-Related ComplicationsTime frame: 30 Days
- Number of Subjects Free from Chronic Aveir DR System-Related ComplicationsTime frame: 5 Years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Abbott
Sylmar, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.